<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02404805</url>
  </required_header>
  <id_info>
    <org_study_id>15-0106</org_study_id>
    <secondary_id>152252</secondary_id>
    <nct_id>NCT02404805</nct_id>
  </id_info>
  <brief_title>Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers</brief_title>
  <official_title>Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/Hepatitis C Virus (HCV) Seronegative Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator believes simeprevir concentrations are unchanged when administered in&#xD;
      combination with dolutegravir relative to administration alone. The investigator believes&#xD;
      dolutegravir concentrations are unchanged when administered in combination with simeprevir.&#xD;
      Additionally, the investigator believes simeprevir and dolutegravir are safe when&#xD;
      administered alone and in combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the potential for drug interactions between simeprevir and dolutegravir,&#xD;
      participants will receive each drug alone and the drugs in combination for 7 days. The&#xD;
      pharmacokinetics of simeprevir and dolutegravir when given in combination vs. alone will be&#xD;
      compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Simeprevir AUC Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose on day 7</time_frame>
    <description>Determine simeprevir area-under-the concentration time curve (AUC) when administered alone and when being co-administered with Dolutegravier.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dolutegravir AUC Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose on day 7</time_frame>
    <description>Determine Dolutegravir area-under-the concentration time curve (AUC) when administered alone and when co-administered with simeprevir.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>HIV</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Sequence 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 1,2,3: simeprevir only, then dolutegravir only, then both simeprevir and dolutegravir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 1,3,2: simeprevir only, then both simeprevir and dolutegravir, then dolutegravir only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 2,1,3: dolutegravir only, then simeprevir only, then both simeprevir and dolutegravir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 2,3,1: dolutegravir only, then both simeprevir and dolutegravir, then simeprevir only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 3,1,2: both simeprevir and dolutegravir, then simeprevir only, then dolutegravir only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 3,2,1: Both simeprevir and dolutegravir, then dolutegravir only, then simeprevir only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dolutegravir</intervention_name>
    <description>dolutegravir tablets 50mg, once daily x 7 days.</description>
    <arm_group_label>Sequence 1a</arm_group_label>
    <arm_group_label>Sequence 1b</arm_group_label>
    <arm_group_label>Sequence 2a</arm_group_label>
    <arm_group_label>Sequence 2b</arm_group_label>
    <arm_group_label>Sequence 3a</arm_group_label>
    <arm_group_label>Sequence 3b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simeprevir</intervention_name>
    <description>simeprevir tablets 150mg, once daily x 7 days.</description>
    <arm_group_label>Sequence 1a</arm_group_label>
    <arm_group_label>Sequence 1b</arm_group_label>
    <arm_group_label>Sequence 2a</arm_group_label>
    <arm_group_label>Sequence 2b</arm_group_label>
    <arm_group_label>Sequence 3a</arm_group_label>
    <arm_group_label>Sequence 3b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women ages 18-60 years&#xD;
&#xD;
          -  Absence of HIV-1 and HCV antibodies at screening,&#xD;
&#xD;
          -  Ability and willingness to give written informed consent before the first&#xD;
             trial-related activity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Active alcohol or drug abuse that, in the opinion of the investigators, would&#xD;
             interfere with adherence to study requirements&#xD;
&#xD;
          -  Participation in any investigational drug study within 30 days prior to study entry&#xD;
&#xD;
          -  Currently active or chronic gastrointestinal, cardiovascular, neurologic, psychiatric,&#xD;
             metabolic, renal, hepatic, respiratory, inflammatory, or infectious disease or&#xD;
             malignancy requiring pharmacologic treatment, and/or if in the opinion of the&#xD;
             investigator, would affect study participation, safety, or integrity of results&#xD;
&#xD;
          -  Use of concomitant medication, including investigational, prescription, and&#xD;
             over-the-counter products and dietary supplements with the following exceptions:&#xD;
             aspirin, acetaminophen, ibuprofen, hormonal oral contraceptives&#xD;
&#xD;
          -  Concomitant medications other than those listed above must have been discontinued at&#xD;
             least 14 days before study entry&#xD;
&#xD;
          -  Currently active dermatitis or urticaria or diagnosis of eczema or psoriasis,&#xD;
&#xD;
          -  History of significant drug allergy (i.e., anaphylaxis and/or angioedema)&#xD;
&#xD;
          -  Subjects with the following laboratory abnormalities at screening as defined by the&#xD;
             2004 Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse&#xD;
             Events (&quot;DAIDS grading table&quot;) and in accordance with the normal ranges of the trial&#xD;
             clinical laboratory: serum creatinine grade 1 or greater (≥ 1.1 x upper limit of&#xD;
             laboratory normal range (ULN)); hemoglobin grade 1 or greater (≤ 10.9 g/dL); platelet&#xD;
             count grade 1 or greater (≤ 124.999 x 109/L); absolute neutrophil count grade 1 or&#xD;
             greater (≤ 1.3 x 109/L); aspartate aminotransferase (AST) or alanine aminotransferase&#xD;
             (ALT) grade 1 or greater (≥ 1.25 x ULN); total bilirubin grade 1 or greater (≥ 1.1 x&#xD;
             ULN), any other laboratory abnormality of grade 2 or above.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer J Kiser, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2015</study_first_posted>
  <results_first_submitted>October 24, 2018</results_first_submitted>
  <results_first_submitted_qc>February 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 17, 2021</results_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dolutegravir</keyword>
  <keyword>simeprevir</keyword>
  <keyword>HIV</keyword>
  <keyword>HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1a</title>
          <description>Sequence 1,2,3: simeprevir only, then dolutegravir only, then both simeprevir and dolutegravir.&#xD;
dolutegravir: dolutegravir tablets 50mg, once daily x 7 days.&#xD;
simeprevir: simeprevir tablets 150mg, once daily x 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 1b</title>
          <description>Sequence 1,3,2: simeprevir only, then both simeprevir and dolutegravir, then dolutegravir only.&#xD;
dolutegravir: dolutegravir tablets 50mg, once daily x 7 days.&#xD;
simeprevir: simeprevir tablets 150mg, once daily x 7 days.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 2a</title>
          <description>Sequence 2,1,3: dolutegravir only, then simeprevir only, then both simeprevir and dolutegravir.&#xD;
dolutegravir: dolutegravir tablets 50mg, once daily x 7 days.&#xD;
simeprevir: simeprevir tablets 150mg, once daily x 7 days.</description>
        </group>
        <group group_id="P4">
          <title>Sequence 2b</title>
          <description>Sequence 2,3,1: dolutegravir only, then both simeprevir and dolutegravir, then simeprevir only.&#xD;
dolutegravir: dolutegravir tablets 50mg, once daily x 7 days.&#xD;
simeprevir: simeprevir tablets 150mg, once daily x 7 days.</description>
        </group>
        <group group_id="P5">
          <title>Sequence 3a</title>
          <description>Sequence 3,1,2: both simeprevir and dolutegravir, then simeprevir only, then dolutegravir only.&#xD;
dolutegravir: dolutegravir tablets 50mg, once daily x 7 days.&#xD;
simeprevir: simeprevir tablets 150mg, once daily x 7 days.</description>
        </group>
        <group group_id="P6">
          <title>Sequence 3b</title>
          <description>Sequence 3,2,1: Both simeprevir and dolutegravir, then dolutegravir only, then simeprevir only.&#xD;
dolutegravir: dolutegravir tablets 50mg, once daily x 7 days.&#xD;
simeprevir: simeprevir tablets 150mg, once daily x 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence 1a</title>
          <description>Sequence 1,2,3: simeprevir only, then dolutegravir only, then both simeprevir and dolutegravir.&#xD;
dolutegravir: dolutegravir tablets 50mg, once daily x 7 days.&#xD;
simeprevir: simeprevir tablets 150mg, once daily x 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Sequence 1b</title>
          <description>Sequence 1,3,2: simeprevir only, then both simeprevir and dolutegravir, then dolutegravir only.&#xD;
dolutegravir: dolutegravir tablets 50mg, once daily x 7 days.&#xD;
simeprevir: simeprevir tablets 150mg, once daily x 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Sequence 2a</title>
          <description>Sequence 2,1,3: dolutegravir only, then simeprevir only, then both simeprevir and dolutegravir.&#xD;
dolutegravir: dolutegravir tablets 50mg, once daily x 7 days.&#xD;
simeprevir: simeprevir tablets 150mg, once daily x 7 days.</description>
        </group>
        <group group_id="B4">
          <title>Sequence 2b</title>
          <description>Sequence 2,3,1: dolutegravir only, then both simeprevir and dolutegravir, then simeprevir only.&#xD;
dolutegravir: dolutegravir tablets 50mg, once daily x 7 days.&#xD;
simeprevir: simeprevir tablets 150mg, once daily x 7 days.</description>
        </group>
        <group group_id="B5">
          <title>Sequence 3a</title>
          <description>Sequence 3,1,2: both simeprevir and dolutegravir, then simeprevir only, then dolutegravir only.&#xD;
dolutegravir: dolutegravir tablets 50mg, once daily x 7 days.&#xD;
simeprevir: simeprevir tablets 150mg, once daily x 7 days.</description>
        </group>
        <group group_id="B6">
          <title>Sequence 3b</title>
          <description>Sequence 3,2,1: Both simeprevir and dolutegravir, then dolutegravir only, then simeprevir only.&#xD;
dolutegravir: dolutegravir tablets 50mg, once daily x 7 days.&#xD;
simeprevir: simeprevir tablets 150mg, once daily x 7 days.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" lower_limit="18" upper_limit="60"/>
                    <measurement group_id="B2" value="34.3" lower_limit="24" upper_limit="42"/>
                    <measurement group_id="B3" value="36.4" lower_limit="29" upper_limit="52"/>
                    <measurement group_id="B4" value="35.6" lower_limit="22" upper_limit="49"/>
                    <measurement group_id="B5" value="35.7" lower_limit="26" upper_limit="45"/>
                    <measurement group_id="B6" value="33.8" lower_limit="25" upper_limit="44"/>
                    <measurement group_id="B7" value="34.3" lower_limit="18" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>ETHNICITY</title>
              <category_list>
                <category>
                  <title>CAUCASIAN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HISPANIC</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Simeprevir AUC Pharmacokinetics</title>
        <description>Determine simeprevir area-under-the concentration time curve (AUC) when administered alone and when being co-administered with Dolutegravier.</description>
        <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose on day 7</time_frame>
        <population>Only arms that included Simeprevir administration are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Simeprevir Administered Alone</title>
            <description>simeprevir: simeprevir tablets 150mg, once daily x 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Simeprevir and Dolutegravier Co-administered</title>
            <description>Dolutegravir and simeprevir together:&#xD;
dolutegravir tablets 50mg, once daily and simeprevir tablets 150mg, once daily x 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Simeprevir AUC Pharmacokinetics</title>
          <description>Determine simeprevir area-under-the concentration time curve (AUC) when administered alone and when being co-administered with Dolutegravier.</description>
          <population>Only arms that included Simeprevir administration are included.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30946" spread="80"/>
                    <measurement group_id="O2" value="30333" spread="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dolutegravir AUC Pharmacokinetics</title>
        <description>Determine Dolutegravir area-under-the concentration time curve (AUC) when administered alone and when co-administered with simeprevir.</description>
        <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose on day 7</time_frame>
        <population>Only arms that included Dolutegravir administration are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Dolutegravir Administered Alone</title>
            <description>dolutegravir: dolutegravir tablets 50mg, once daily x 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Simeprevir and Dolutegravier Co-administered</title>
            <description>Dolutegravir and simeprevir co-administered:&#xD;
dolutegravir tablets 50mg, once daily and simeprevir tablets 150mg, once daily x 7 da</description>
          </group>
        </group_list>
        <measure>
          <title>Dolutegravir AUC Pharmacokinetics</title>
          <description>Determine Dolutegravir area-under-the concentration time curve (AUC) when administered alone and when co-administered with simeprevir.</description>
          <population>Only arms that included Dolutegravir administration are included.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68186" spread="30"/>
                    <measurement group_id="O2" value="78433" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time of consenting to study exit (Phone follow up 7 days after final intensive PK visit, max 3 months)</time_frame>
      <desc>AEs were graded per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0, November, 2014. Available: http://rsc.tech-res.com/safetyandpharmacovigilance/.</desc>
      <group_list>
        <group group_id="E1">
          <title>Simeprevir Only</title>
          <description>Simeprevir tablets 150mg, once daily x 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Dolutegravir Only</title>
          <description>Dolutegravir tablets 50mg, once daily x 7 days.</description>
        </group>
        <group group_id="E3">
          <title>Dolutegravir and Simeprevir Co-administered:</title>
          <description>Dolutegravir and simeprevir co-administered:&#xD;
dolutegravir tablets 50mg, once daily, and simeprevir tablets 150mg, once daily, x 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal issues (stomach pain, gas, vomiting, nausea, diarrhea)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abnormal Labs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jennifer Kiser</name_or_title>
      <organization>University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences</organization>
      <phone>(303) 724-6131</phone>
      <email>jennifer.kiser@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

